Our team is committed to advancing genomic medicine.
Led by renowned experts in the fields of genomics, epigenetic editing, and drug discovery, we are driven pioneers committed to making the future of genomic medicine real and delivering hope to patients suffering from serious illnesses.
Kevin Bitterman, Ph.D.
Partner, Atlas Venture
Thomas Cahill, M.D., Ph.D.
Founder and Managing Partner, Newpath Partners
Founder, Cormorant Asset Management
George Golumbeski, Ph.D.
Partner, DROIA Ventures
John Maraganore, Ph.D.
Former Founding CEO, Alnylam Pharmaceuticals
Co-founder and Former Founding CEO and Board Member, Spark Therapeutics
Partner, Sofinnova Partners
Catherine Stehman-Breen, M.D., M.S.
Chief Executive Officer, Chroma